Paper30174151
Histidine N(τ)-cyclized macrocycles as a new genre of polo-like kinase 1 polo-box domain-binding inhibitors.
Hymel D and 4 others. Bioorg Med Chem Lett, 2018. Cited by 14 papers, by iCite.
Cite this record
ConductScience Library. Histidine N(τ)-cyclized macrocycles as a new genre of polo-like kinase 1 polo-box domain-binding inhibitors. Papers, record 30174151. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/30174151
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Histidine N(τ)-cyclized macrocycles as a new genre of polo-like kinase 1 polo-box domain-binding inhibitors.
- PubMed
- Publication types
- Journal Article, Research Support, N.I.H., Extramural, Research Support, N.I.H., Intramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.
- PubMed
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Cell Cycle Proteins | Major topic |
| Histidine | Major topic |
| Macrocyclic Compounds | Major topic |
| Protein Serine-Threonine Kinases | Major topic |
| Proto-Oncogene Proteins | Major topic |
| Cyclization | |
| Enzyme-Linked Immunosorbent Assay | |
| Polo-Like Kinase 1 |
Source PubMed
Grants5
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| P41 GM103403 | NIGMS NIH HHS | United States | P41GM103403 | PubMed and NIH | NIH RePORTER |
| R01 ES015339 | NIEHS NIH HHS | United States | R01ES015339 | PubMed and NIH | NIH RePORTER |
| R35 ES028374 | NIEHS NIH HHS | United States | R35ES028374 | PubMed and NIH | NIH RePORTER |
| R01 GM104047 | NIGMS NIH HHS | United States | R01GM104047 | PubMed and NIH | NIH RePORTER |
| Z01 BC006198 | Intramural NIH HHS | United States | ZIABC006198 | PubMed and NIH | NIH RePORTER |
References31
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 27017542 | Small molecules that target phosphorylation dependent protein-protein interaction. | Bioorg Med Chem | 2016 | https://conductscience.org/library/papers/27017542 | PubMed |
| 2 | 25814554 | Phospho-tyrosine dependent protein-protein interaction network. | Mol Syst Biol | 2015 | https://conductscience.org/library/papers/25814554 | PubMed |
| 3 | 22570300 | Peptoid-Peptide hybrid ligands targeting the polo box domain of polo-like kinase 1. | Chembiochem | 2012 | https://conductscience.org/library/papers/22570300 | PubMed |
| 4 | 19597481 | Structural and functional analyses of minimal phosphopeptides targeting the polo-box domain of polo-like kinase 1. | Nat Struct Mol Biol | 2009 | https://conductscience.org/library/papers/19597481 | PubMed |
| 5 | 28285924 | Enhancing polo-like kinase 1 selectivity of polo-box domain-binding peptides. | Bioorg Med Chem | 2017 | https://conductscience.org/library/papers/28285924 | PubMed |
| 6 | 26119925 | Structure-Based Design of Inhibitors of Protein-Protein Interactions: Mimicking Peptide Binding Epitopes. | Angew Chem Int Ed Engl | 2015 | https://conductscience.org/library/papers/26119925 | PubMed |
| 7 | 27624074 | Application of oxime-diversification to optimize ligand interactions within a cryptic pocket of the polo-like kinase 1 polo-box domain. | Bioorg Med Chem Lett | 2016 | https://conductscience.org/library/papers/27624074 | PubMed |
| 8 | 24827688 | Design and synthesis of Fmoc-Thr[PO(OH)(OPOM)] for the preparation of peptide prodrugs containing phosphothreonine in fully protected form. | Chem Biodivers | 2014 | https://conductscience.org/library/papers/24827688 | PubMed |
| 9 | 25283071 | Mono-anionic phosphopeptides produced by unexpected histidine alkylation exhibit high Plk1 polo-box domain-binding affinities and enhanced antiproliferative effects in HeLa cells. | Biopolymers | 2014 | https://conductscience.org/library/papers/25283071 | PubMed |
| 10 | 26152807 | Neighbor-directed histidine N (τ)-alkylation: A route to imidazolium-containing phosphopeptide macrocycles. | Biopolymers | 2015 | https://conductscience.org/library/papers/26152807 | PubMed |
| 11 | 27718641 | Discovery and optimization of peptide macrocycles. | Expert Opin Drug Discov | 2016 | https://conductscience.org/library/papers/27718641 | PubMed |
| 12 | 28721210 | Current progress and future perspectives in the development of anti-polo-like kinase 1 therapeutic agents. | F1000Res | 2017 | https://conductscience.org/library/papers/28721210 | PubMed |
| 13 | 22292814 | Identification of high affinity polo-like kinase 1 (Plk1) polo-box domain binding peptides using oxime-based diversification. | ACS Chem Biol | 2012 | https://conductscience.org/library/papers/22292814 | PubMed |
| 14 | 26478211 | Recent Advances and New Strategies in Targeting Plk1 for Anticancer Therapy. | Trends Pharmacol Sci | 2015 | https://conductscience.org/library/papers/26478211 | PubMed |
| 15 | 25664609 | Targeting protein-protein interfaces using macrocyclic peptides. | Biopolymers | 2015 | https://conductscience.org/library/papers/25664609 | PubMed |
| 16 | 14532005 | The molecular basis for phosphodependent substrate targeting and regulation of Plks by the Polo-box domain. | Cell | 2003 | https://conductscience.org/library/papers/14532005 | PubMed |
| 17 | 23159568 | Non-proteinogenic amino acids in the pThr-2 position of a pentamer peptide that confer high binding affinity for the polo box domain (PBD) of polo-like kinase 1 (Plk1). | Bioorg Med Chem Lett | 2012 | https://conductscience.org/library/papers/23159568 | PubMed |
| 18 | 22743087 | Effects on polo-like kinase 1 polo-box domain binding affinities of peptides incurred by structural variation at the phosphoamino acid position. | Bioorg Med Chem | 2013 | https://conductscience.org/library/papers/22743087 | PubMed |
| 19 | 23907438 | Design and synthesis of a reagent for solid-phase incorporation of the phosphothreonine mimetic (2S,3R)-2-amino-3-methyl-4-phosphonobutyric acid (Pmab) into peptides in a bio-reversible phosphonyl-bis-pivaloyloxymethyl (POM) prodrug form. | Amino Acids | 2013 | https://conductscience.org/library/papers/23907438 | PubMed |
| 20 | 25211362 | Design and synthesis of a cell-permeable, drug-like small molecule inhibitor targeting the polo-box domain of polo-like kinase 1. | PLoS One | 2014 | https://conductscience.org/library/papers/25211362 | PubMed |
Cited by9
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 14 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 39764864 | Fine-tuning probes for fluorescence polarization binding assays of bivalent ligands against polo-like kinase 1 using full-length protein. | Bioorg Med Chem | 2025 | https://conductscience.org/library/papers/39764864 | PubMed |
| 39092437 | Affinity enhancement of polo-like kinase 1 polo box domain-binding ligands by a bivalent approach using a covalent kinase-binding component. | RSC Chem Biol | 2024 | https://conductscience.org/library/papers/39092437 | PubMed |
| 38393054 | Identification of PLK1-PBD Inhibitors from the Library of Marine Natural Products: 3D QSAR Pharmacophore, ADMET, Scaffold Hopping, Molecular Docking, and Molecular Dynamics Study. | Mar Drugs | 2024 | https://conductscience.org/library/papers/38393054 | PubMed |
| 36067356 | Discovery of Cyclic Peptide Inhibitors Targeting PD-L1 for Cancer Immunotherapy. | J Med Chem | 2022 | https://conductscience.org/library/papers/36067356 | PubMed |
| 35408522 | Insights on the Synthesis of N-Heterocycles Containing Macrocycles and Their Complexion and Biological Properties. | Molecules | 2022 | https://conductscience.org/library/papers/35408522 | PubMed |
| 35029981 | Novel Macrocyclic Peptidomimetics Targeting the Polo-Box Domain of Polo-Like Kinase 1. | J Med Chem | 2022 | https://conductscience.org/library/papers/35029981 | PubMed |
| 34346472 | Design and synthesis of a new orthogonally protected glutamic acid analog and its use in the preparation of high affinity polo-like kinase 1 polo-box domain - binding peptide macrocycles. | Org Biomol Chem | 2021 | https://conductscience.org/library/papers/34346472 | PubMed |
| 33842469 | Regulation of the SIAH2-HIF-1 Axis by Protein Kinases and Its Implication in Cancer Therapy. | Front Cell Dev Biol | 2021 | https://conductscience.org/library/papers/33842469 | PubMed |
| 31014020 | Development of Highly Selective 1,2,3-Triazole-containing Peptidic Polo-like Kinase 1 Polo-box Domain-binding Inhibitors. | Molecules | 2019 | https://conductscience.org/library/papers/31014020 | PubMed |
Genes5
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| AGXT | 189 | PubTator's text mining | https://conductscience.org/library/genes/189 | NCBI Gene |
| HAL | 3034 | PubTator's text mining | https://conductscience.org/library/genes/3034 | NCBI Gene |
| PLK1 | 5347 | PubTator's text mining | https://conductscience.org/library/genes/5347 | NCBI Gene |
| PLK2 | 10769 | PubTator's text mining | https://conductscience.org/library/genes/10769 | NCBI Gene |
| PLK3 | 1263 | PubTator's text mining | https://conductscience.org/library/genes/1263 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/30174151
GET https://conductscience.org/api/papers/v1/30174151/references?page=2